![]() |
|
|
Vol. 288, Issue 3, 1045-1052, March 1999
Department of Internal Medicine and Therapeutics, Section of
Pharmacology and Toxicology, University of Pavia, Pavia PV, Italy
In five fasting, conscious dogs, we compared the prokinetic action of
two selective 5-hydroxytryptamine-4 (5-HT4) receptor agonists with low affinity for 5-HT3 receptors ML10302
(2-piperidinoethyl 4-amino-5-chloro-2-methoxybenzoate) and SR59768
(2-[(3S)-3-hydroxypiperidino]ethyl 4-amino-5-chloro-2-methoxybenzoate) in the duodenum and jejunum, using
cisapride as a reference compound. Heart rate and rate-corrected QT
(QTc) also were monitored to assess whether
or not the cardiac effects of cisapride are shared by other
5-HT4 receptor agonists. Both ML10302 and SR59768
dose-dependently stimulated spike activity in the duodenum with similar
potencies (dose range, 3-300 nmol/kg i.v.; ED50 values: 24 and 23 nmol/kg i.v., respectively), mimicking the effect of cisapride
(30-3000 nmol/kg i.v.). The maximal effect was achieved with the dose
of 100 nmol/kg i.v. for both compounds. Similar findings were obtained
in the jejunum. Atropine and GR125487 (1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl-methyl
5-fluoro-2-methoxy-1H-indole-3-carboxylate, selective 5-HT4 receptor antagonist), at doses having no
effect per se, antagonized intestinal prokinesia by maximal doses of ML10302 and SR59768. Neither ML10302 nor SR59768 had any effect on
heart rate or QTc at any of the doses tested, whereas
cisapride, at the highest dose (3000 nmol/kg), induced tachycardia and
lengthened the QTC (p < .01). In
conclusion, ML10302 and SR59768 share with cisapride a similar
prokinetic action in the canine duodenum and jejunum in vivo. This
effect is mediated by pathways involving activation of
5-HT4 and muscarinic receptors. Unlike cisapride, which
induces tachycardia and prolongs the QTc by a mechanism probably unrelated to 5-HT4 receptor activation, ML10302
and SR59768 are devoid of cardiac effects in this model.